Address: 125284 Москва, ул. Беговая д. 3, строение 1,Russia
Tel: +7 (495) 799-56-99
Web: http://www.astrazeneca.ru/
AstraZeneca has had a presence in Russia since 1993 when representative offices of Swedish Astra AB and British Zeneca were opened. In 1999, these two companies merged and a new ambitious player on the market was formed – AstraZeneca.
AstraZeneca now employs more than 1,000 people across 68 Russian cities. Around 40 of our original products are licensed for sale in Russia.
In 2010, AstraZeneca achieved sales in Russia of more than $200 million and is targeting double-digit growth over the next five years. AstraZeneca has leading position in the hospital and oncology segments and is the fastest-growing company in retail pharmaceutical sector with Nexium and Symbicort as its best sellers.
Achieving continuing growth in Russia is a strategic priority for AstraZeneca. The Marketing Company is committed to contributing to the development of the innovative pharmaceutical sector in Russia, helping to meet the goals of the Russian Government’s Pharma 2020 strategy.
As part of our growth strategy, AstraZeneca is investing more than $150 million in building a new full cycle manufacturing plant in the Kaluga Region. At Phase I (packing) in 2013 the site’s capacity will be 16 million packs per year including medicines for cardiology, oncology, gastroenterology, neuroscience and respiratory. By 2015 full cycle production will be launched with the capacity to produce 500 mln tablets per year.
As well as investing in a new production plant, the company is committed to innovative pharmaceutical research and development in Russia. At the moment AstraZeneca has collaborations with over 150 research institutes to conduct phase II-IV clinical trials.
The company has signed Memoranda of Understanding with the Russian Venture Company and Skolkovo Foundation to help develop the country’s infrastructure for biomedicine and bio-pharmaceutics. A major component of these joint initiatives is the company’s Virtual Research Institute – Avangard Znaniy – a programme supporting promising Russian medical and pharmaceutical researchers.
Being a socially responsible company, AstraZeneca implements a number of large-scale patient health and disease awareness CSR projects, such as “Save Your Hearts” in cardiology and “World Mental Health Day” in neurology.
Oncology segments and is the fastest-growing company in retail pharmaceutical sector with Nexium and Symbicort as its best sellers.
You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in…
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in…
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of…
GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s…
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale…
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the…
Janssen recently signed memorandums of understanding with both the Skolkovo Foundation and ChemRar. Can you describe the strategic parameters and intended outcomes of these agreements? How do they factor into…
Mr. Demidov, you are one of the pioneers of market research studies in Russia. There is a quote you like to use: ‘Market research is a business in the United…
How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the…
With the announcement of the Pharma 2020 strategy to develop the domestic pharmaceutical industry, multinational companies have pledged an excess of $1Bn in investment into local infrastructure. Servier, however, preempted…
See our Cookie Privacy Policy Here
